Blood test to guide early stopping of prostate cancer therapy
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial uses a blood test to measure tumor DNA and see if men with advanced prostate cancer can safely stop treatment with a drug called 177Lu-PSMA-617 earlier than usual, or switch to chemotherapy. It may help reduce side effects while still controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man aged 18 or older with advanced prostate cancer that has spread (metastatic), stopped responding to hormone therapy, and is now castration-resistant.
- Your cancer has gotten worse despite treatment with at least one hormone-blocking drug like enzalutamide or abiraterone, and you are eligible for either 177Lu-PSMA-617 or docetaxel chemotherapy.
- You have not had prior chemotherapy with drugs like docetaxel or cabazitaxel for any stage of prostate cancer.
- You have adequate blood counts (white cells, platelets, red cells), kidney function, and liver function as shown by recent blood tests.
- You do not have serious heart problems, uncontrolled infections, or other major medical conditions that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs: vorinostat (a pill that may make cancer cells easier to target) and 177Lu-PSMA-617 (a radioactive drug that seeks out prostate cancer cells). It is for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy and shows low levels of PSMA on a PET scan.
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
This trial is testing if a higher first dose of Lu-177-PSMA-617, a targeted radiation therapy, can improve outcomes for men with metastatic castration-resistant prostate cancer that shows up on a PSMA PET scan. The goal is to see if it is safe and effective.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
Hear when a new Stage IVB Prostate Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.